Instructions for use Cognum tablets 250 mg blister No. 50
Composition
active ingredient: calcium salt of hopantenic acid;
1 tablet contains 250 mg of calcium salt of hopantenic acid;
excipients: heavy magnesium carbonate, potato starch, talc, calcium stearate.
Dosage form
Pills.
Main physicochemical properties: white tablets, flat-cylindrical in shape with a bevel and a score.
Pharmacotherapeutic group
Psychostimulants and nootropics.
ATX code N06B X.
Pharmacological properties
Pharmacodynamics
The mechanism of action is due to the direct effect of hopantenic acid on the GABAB receptor-channel complex. The drug has a nootropic and anticonvulsant effect, increases the brain's resistance to hypoxia and the action of toxic substances, stimulates the processes of anabolism in neurons, combines a moderate sedative effect with a mild stimulating effect, reduces motor excitability. Increases mental and physical performance. Promotes the normalization of GABA in chronic alcohol intoxication and subsequent ethanol withdrawal. Prolongs the effect of novocaine and sulfonamides by inhibiting their acetylation reactions. Causes inhibition of pathologically increased bladder reflex and detrusor tone.
Pharmacokinetics
Cognum is rapidly absorbed from the gastrointestinal tract, penetrates the blood-brain barrier; higher concentrations are formed in the liver, kidneys and skin. The time to reach Cmax is 1 hour. The drug is not metabolized and is excreted unchanged within 48 hours: 67.5% of the dose taken - with urine, 28.5% - with feces.
Indication
As part of complex therapy:
- cognitive disorders in organic brain lesions (including the consequences of neuroinfection and traumatic brain injuries);
- cerebrovascular insufficiency caused by atherosclerotic changes in the cerebral vessels;
- extrapyramidal disorders (myoclonus epilepsy, Huntington's chorea, hepatolenticular degeneration, Parkinson's disease);
- epilepsy with mental retardation, in complex therapy with anticonvulsant drugs;
- psycho-emotional overload, decreased mental and physical performance (to increase concentration and memorization);
- neurogenic urination disorders: enuresis, pollakiuria, imperative urges, imperative urinary incontinence;
- the drug is indicated for children aged 3 years and older with perinatal encephalopathy, mental retardation of varying degrees of severity, with developmental delay (mental, speech, motor), with various forms of cerebral palsy, with hyperkinetic disorders (attention deficit hyperactivity disorder, tics), with stuttering (mainly clonic form), and neurosis-like conditions.
Contraindication
Hypersensitivity to the components of the drug; acute severe kidney disease.
Special safety measures.
During long-term treatment, simultaneous administration of other nootropic and stimulant drugs is not recommended. Given the nootropic effect of the drug, it is taken mainly in the morning and afternoon hours.
Interaction with other medicinal products and other types of interactions
In conditions of long-term treatment, the simultaneous use of Cognum with other nootropic and stimulant drugs is not recommended.
The drug prolongs the effect of barbiturates, enhances the effect of anticonvulsants and drugs that stimulate the central nervous system, prevents the side effects of phenobarbital, carbamazepine, antipsychotics (neuroleptics), and enhances the effect of local anesthetics (novocaine).
The drug is able to inhibit acetylation reactions, which are components of the inactivation mechanisms of novocaine and sulfonamides, thereby achieving a prolonged effect of the latter.
The effect of Cognum is enhanced in combination with glycine, etidronic acid, and xydifon.
Use during pregnancy or breastfeeding
Cognum is contraindicated during pregnancy or breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
During treatment with the drug, caution should be exercised when driving or operating other mechanisms.
Method of administration and doses
Cognum should be used as part of complex therapy.
Take the tablets 15-30 minutes after meals.
A single dose for children over 12 years of age and adults is 250 mg-1000 mg, for children aged 3 to 12 years – 250-500 mg.
The daily dose for children over 12 years of age and adults is 1500-3000 mg, for children aged 3 to 12 years – 750 mg-3000 mg.
The course of treatment is from 1 to 4 months, in some cases up to 6 months. After 3-6 months, a second course of treatment is possible.
For the consequences of neuroinfections and traumatic brain injuries: children over 3 years of age and adults - 250 mg 3-4 times a day.
For cerebrovascular insufficiency: adults - 250 mg 3-4 times a day.
For epilepsy in combination with anticonvulsants: children aged 3 to 12 years, 250-500 mg 3-4 times a day, children aged 12 years and older and adults - 500 mg-1000 mg 3-4 times a day, daily, for a long time (up to 6 months).
For psycho-emotional overload, decreased mental and physical performance: children over 3 years of age and adults - 250 mg 3 times a day.
For urination disorders: children over 12 years of age and adults - 500 mg-1000 mg 2-3 times a day, children from 3 to 12 years of age - 250-500 mg (daily dose - 25-50 mg/kg of body weight) 2-3 times a day. The course of treatment is from 1 to 3 months.
Children aged 3 to 12 years with perinatal encephalopathy, mental retardation, developmental delay, cerebral palsy are prescribed Cognum 500 mg 4-6 times a day, daily, for 3 months, with delayed speech development - 500 mg 3-4 times a day for 2-3 months.
For hyperkinetic disorders, tics, stuttering, neurosis-like conditions, the drug is prescribed to children aged 3 to 12 years at 250-500 mg 3-6 times a day, daily, for 1-4 months, to children aged 12 and older and adults - 1500-3000 mg per day daily for 1-5 months.
Tactics of prescribing the drug: increasing the dose over 7-12 days, taking the maximum dose for 15-40 days and gradually reducing the dose until Cognum is discontinued over 7-8 days. The break between courses of therapy is from 1 to 3 months.
Children
Use for children aged 3 years and over.
Overdose
Increased symptoms of adverse reactions.
Treatment: activated charcoal, gastric lavage, symptomatic therapy.
Adverse reactions
Allergic reactions are possible, including rhinitis, conjunctivitis, skin rash. If allergic reactions occur, the drug should be discontinued.
During the use of the drug, the following are possible: urticaria, itching, skin hyperemia, facial hyperemia, skin peeling. In this case, the dose should be reduced or the drug should be discontinued. Neurological disorders are possible, including sleep disturbances or drowsiness, noise in the head, which are usually short-term and do not require discontinuation of the drug.
Expiration date
2 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of the reach of children.
Packaging
10 tablets in a blister; 5 blisters in a pack.
Vacation category
According to the recipe.
Producer
PJSC "Kyiv Vitamin Plant".
Location of the manufacturer and address of its place of business
04073, Ukraine, Kyiv, Kopylivska St., 38.
Website: www.vitamin.com.ua.
